Prothena(PRTA)

Focus: Prothena is a Dublin-based public biotech focused on antibody therapeutics targeting neurology and immunology indications, particularly amyloidosis and Parkinson's Disease. The company operates as a mid-cap biotech with a heavily R&D-focused model and emerging commercial revenue.

Neurology Immunology

Profile data last refreshed 21h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

Recent layoff filing — 91 affected

6/2/2025 — CA · 91 affected · Layoff Amendment

Source: state DOL filings via Big Local News

About Prothena

AI assessmentNot Hiring

No open roles listed right now. Follow Prothena to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$91M

Pipeline & Clinical Trials

Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinso

Parkinson's Disease

N/A

Clinical Trials (1)

NCT03043768Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson's Disease

N/A

Help build intelligence for Prothena

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Advanced pipeline in high-unmet-need rare diseases with 2 Phase 3 programs (Birtamimab and NEOD001 in AL Amyloidosis, Prasinezumab in Parkinson's) offering near-term regulatory catalysts
Strong cash position of $619M provides runway for clinical programs and reduces near-term restructuring risk despite operating losses
Specialized antibody platform in neurology/immunology creates deep technical expertise and intellectual property moat in differentiated therapeutic areas

Watch Out For

No approved products generating meaningful revenue ($91M in FY2025 vs. $221M R&D spend) means limited commercial infrastructure and job security tied entirely to pipeline success
Significant operating losses (-$147M net income in FY2025) despite 69% YoY revenue growth signals cash burn will eventually pressure headcount if Phase 3 programs fail

Generated by Claude from Prothena's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

non-interventional

AL Amyloidosis

N/A

Clinical Trials (1)

NCT02574676Quality of Life (QOL) Registry for Patients With AL Amyloidosis

N/A

PRX003

Psoriasis

PHASE_1

Clinical Trials (1)

NCT02458677Single Ascending Dose Study of PRX003 in Healthy Subjects

Phase 1